IL1RAPL2 Antibody

Basic Research Questions

• What is IL1RAPL2 and why is it significant in neuroscience research?

  IL1RAPL2 (Interleukin-1 receptor accessory protein-like 2) is a member of the interleukin-1 receptor family with significant expression in the brain. It is structurally composed of a 17-amino acid signal peptide, a 339-amino acid extracellular region containing three Ig-like domains, an 18-amino acid transmembrane domain, and a 312-amino acid cytoplasmic tail . IL1RAPL2 gains research significance due to its genetic location on chromosome Xq22, a region associated with X-linked non-syndromic mental retardation, sharing this characteristic with its homolog IL1RAPL1 . Recent studies demonstrate IL1RAPL2's involvement in excitatory pre-synapse formation and dendritic spine development, highlighting its potential role in neuronal connectivity and synaptic plasticity .

• What applications are IL1RAPL2 antibodies commonly validated for?

  IL1RAPL2 antibodies have been validated for multiple experimental applications. Western blotting (WB) is frequently used to detect the protein's expression in cell lysates and tissue homogenates, with predicted band size of approximately 79 kDa . Immunohistochemistry (IHC-P) applications have successfully detected IL1RAPL2 in diverse tissues including human skin, brain (cortex), and pancreas, showing specific localization to endothelial cells in vasculature, neuronal cell bodies, and exocrine glandular cells respectively . Flow cytometry has demonstrated effective detection in various cell lines including HepG2 human hepatocellular carcinoma and Hepa 1-6 mouse hepatoma cells . Additionally, enzyme-linked immunosorbent assays (ELISA/CLIA) have been developed with sensitivity levels below 5.4 pg/ml for quantitative analysis of IL1RAPL2 in tissue homogenates and biological fluids .

• What is the typical cross-reactivity profile of IL1RAPL2 antibodies?

  IL1RAPL2 antibodies demonstrate varying degrees of cross-reactivity with related proteins and across species. In direct ELISAs, approximately 35% cross-reactivity with recombinant mouse IL-1RAPL2/IL-1R9 has been observed . Western blot analyses have shown approximately 5% cross-reactivity with recombinant human IL-1R7 and less than 1% cross-reactivity with recombinant human IL-1R2 and IL-1R8 . This cross-reactivity profile is important for experimental design, particularly when studying tissues expressing multiple interleukin receptor family members. Species reactivity typically includes human and mouse (with ~95% amino acid sequence identity between these species) . Some antibodies have demonstrated broader reactivity across species including rat, dog, rabbit, horse, and guinea pig . To minimize potential cross-reactivity issues in experimental designs, researchers should perform careful validation with appropriate positive and negative controls relevant to their specific experimental system.

Intermediate Research Questions

• How can IL1RAPL2 antibodies be optimized for neuronal tissue immunostaining?

  Optimizing IL1RAPL2 antibody staining in neuronal tissue requires specific methodological considerations. For paraffin-embedded brain tissue sections, particularly cortex samples, heat-induced epitope retrieval is essential using specialized reagents such as Antigen Retrieval Reagent-Basic . Recommended antibody concentrations range from 3-5 μg/mL with incubation times of approximately 1 hour at room temperature . For detection systems, anti-species IgG HRP polymer antibodies (such as VisUCyte™ HRP Polymer) provide robust signal amplification with minimal background. DAB (3,3'-diaminobenzidine) works effectively as a chromogen, producing brown staining that clearly contrasts with hematoxylin counterstaining (blue) . For fluorescent applications, secondary antibodies conjugated with fluorophores like Allophycocyanin have demonstrated good results in flow cytometry applications and may be adapted for immunofluorescence . When analyzing results, neuronal IL1RAPL2 staining localizes primarily to neuronal cell bodies in cortical regions, providing an important positive control reference pattern .

• What approaches can resolve contradictory IL1RAPL2 expression data across different antibodies?

  When faced with contradictory IL1RAPL2 expression data from different antibodies, a systematic troubleshooting approach is required. First, compare the epitope regions targeted by each antibody - some target the extracellular domain (amino acids 100-250), while others target the TIR domain or C-terminal regions . Epitope accessibility may vary depending on tissue fixation methods, protein conformation, or potential masking by interacting proteins like PTPδ or RhoGAP2 . Second, validate antibodies using overexpression systems by comparing control (vector-only) versus IL1RAPL2-overexpressing cells, as demonstrated with HEK-293T cells . Third, perform knockout/knockdown validation where possible to confirm specificity. Fourth, compare staining patterns across multiple tissues with known expression patterns - endothelial cells in skin vasculature, neuronal cell bodies in brain cortex, and exocrine glandular cells in pancreas provide useful reference points . Finally, use orthogonal detection methods (e.g., mRNA expression via RT-PCR) to correlate with protein detection results.

• What parameters are critical for quantitative analysis of IL1RAPL2 using flow cytometry?

  Successful quantitative analysis of IL1RAPL2 using flow cytometry depends on several critical parameters. Cell preparation is crucial - for native expression, HepG2 (human hepatocellular carcinoma) and Hepa 1-6 (mouse hepatoma) cell lines are validated models, while proper single-cell suspensions are essential for reliable detection . Optimal antibody concentration should be determined empirically, with titration experiments to identify the concentration providing maximum separation between positive and negative populations. Based on published protocols, goat anti-human IL1RAPL2 antibodies followed by allophycocyanin-conjugated secondary antibodies have demonstrated effective staining . Appropriate negative controls are essential, including isotype controls (such as AB-108-C) to establish background staining levels . Gating strategies should first identify viable cells (using appropriate viability dyes), followed by single cells (FSC-H vs. FSC-A), and then analyze IL1RAPL2 expression. For quantitative analysis, mean fluorescence intensity (MFI) should be calculated and normalized to control populations. When analyzing results, histogram overlays comparing test samples with isotype controls provide clear visualization of specific staining, as demonstrated in published flow cytometry data .

Technical Applications and Troubleshooting

• What controls are essential when validating a new IL1RAPL2 antibody for neuronal tissue studies?

  Comprehensive validation of a new IL1RAPL2 antibody for neuronal tissue studies requires multiple controls. Positive tissue controls should include human brain cortex, where IL1RAPL2 shows specific staining in neuronal cell bodies , and potentially pancreas, where it localizes to exocrine glandular cells . Negative control tissues with minimal IL1RAPL2 expression should be included based on expression databases. Peptide competition assays, where the antibody is pre-incubated with the immunizing peptide (e.g., recombinant IL1RAPL2 fragments corresponding to amino acids 100-250 or Thr17-Glu356), should abolish specific staining . Heterologous expression systems comparing IL1RAPL2-transfected HEK-293T cells versus vector-only controls provide definitive validation of antibody specificity . Isotype control antibodies (matching the host species and immunoglobulin class) should be used at identical concentrations to the test antibody to establish background staining levels . Cross-reactivity assessment with related family members, particularly IL1RAPL1 (63% homology), is essential given their structural similarity . Finally, orthogonal validation using multiple antibodies targeting different IL1RAPL2 epitopes can confirm staining patterns, while correlation with mRNA expression data provides additional confirmation of specificity.

• How can IL1RAPL2 antibodies be employed to investigate its role in X-linked intellectual disability models?

  Investigating IL1RAPL2's role in X-linked intellectual disability models using antibodies requires a multi-faceted experimental approach. Immunohistochemical mapping of IL1RAPL2 expression in relevant brain regions (cortex, hippocampus) should be performed in both control and disorder models, noting that IL1RAPL2 shows specific localization to neuronal cell bodies in cortical regions . For genetic models, researchers should consider that IL1RAPL2 is located on chromosome Xq22, a region associated with X-linked non-syndromic mental retardation . Co-immunoprecipitation with IL1RAPL2 antibodies followed by mass spectrometry can identify altered protein-protein interaction networks in disease models, particularly focusing on known binding partners like PTPδ and RhoGAP2 . In vitro functional assays measuring synaptic development should be employed, as both IL1RAPL1 and IL1RAPL2 can induce excitatory pre-synapse differentiation and dendritic spine formation . For examining specific signaling mechanisms, phospho-specific antibodies against downstream targets (e.g., c-Jun N-terminal kinase, PSD-95) can assess pathway integrity in disease models . Finally, therapeutic intervention studies might use IL1RAPL2 antibodies to track receptor expression and localization following experimental treatments. When comparing with IL1RAPL1 (which has established links to X-linked mental retardation), researchers should note the 63% sequence homology while recognizing their potentially distinct contributions to neuronal development and function .

Technical Tables and Reference Data